Covance plans closures – and expansions – as it aims to 'right-size'

By Melissa Fassbender contact

- Last updated on GMT

LabCorp has expanded its LaunchPad initiative to include Covance Drug Development. (Image: iStock/Pinkypills)
LabCorp has expanded its LaunchPad initiative to include Covance Drug Development. (Image: iStock/Pinkypills)

Related tags: Management

LabCorp’s Covance is implementing a two-phase plan intended to create operational efficiencies over the next three years.

In an SEC filing yesterday, the Laboratory Corporation of America Holdings (LabCorp) announced that it is expanding its LaunchPad business process improvement initiative to include its Covance Drug Development segment.

According to the company, the first phase of the initiative focuses on Covance’s near-term outlook.

Per its earnings release, this phase is expected to generate pre-tax savings of approximately $20m in 2017 and approximately $45m annually thereafter.

In connection with the implementation of the first phase, on April 24, 2017, the Company committed to carry out a reduction in workforce in 2017​,” the SEC filing explained.

In the first phase of this work, there will be a limited number of position reductions across the Covance business​,” Pattie Kushner, a spokesperson for LabCorp told Outsourcing-Pharma.com in a statement.

Additionally, Kushner said the company is “right-sizing​” its operational footprint as part of phase two – “consolidating some facilities while expanding others​,” she said, noting the recent expansion​ at the company’s UK-based operations.

These actions align with our integration strategy, the anticipated flow of client work across our locations and areas targeted for growth​,” she said.

Related facility closure costs are expected to be approximately $16.0m in 2017. 

The second phase focuses on long-term structural changes “designed to create a more efficient business model​,” according to the filing.

However, Kushner said it is import to note that the “vast majority​” of Covance’s 15,000 employees and clients will not be affected by the restructuring and service delivery “will continue without interruption​.”

Those employees who may be impacted have been notified, she said, adding that the actions will be completed by the end of 2017.

More details are expected later in the year.

In the immediate term, our primary focus is to support employees who are transitioning and to work with clients who may have changes in their project teams to avoid any disruption to service​.”

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars